Oxford BioDynamics PLC PDMR Dealing / Grant of Share Options (3190S)
08 July 2020 - 4:00PM
UK Regulatory
TIDMOBD
RNS Number : 3190S
Oxford BioDynamics PLC
08 July 2020
8 July 2020
Oxford BioDynamics Plc
( "OBD" or the "Company" and, together with its subsidiaries,
the "Group")
PDMR Dealing / Grant of Share Options
Oxford BioDynamics Plc (AIM: OBD) (the "Company"), a
biotechnology company focused on the discovery and development of
epigenetic biomarkers, based on regulatory 3D genome architecture,
using its liquid biopsy platform EpiSwitch(TM), announces that it
has today granted 210,000 options over its ordinary shares of 1
pence each ("Ordinary Shares"), to Non-Executive Chairman, Dr Peter
Pack. The options were granted under the Company's 2016
Non-Employee Share Option Plan with an exercise price of GBP1 per
share.
One-third of the options granted will vest and become
exercisable on the first anniversary of the grant date; one-third
on the second anniversary and one-third on the third anniversary.
Vested options will remain exercisable up to and including the
tenth anniversary of the date of grant.
Following this grant, Peter Pack holds a total of 250,000
options over Ordinary Shares and is interested in 15,000 Ordinary
Shares, representing 0.02% of the Company's current issued share
capital.
The notification below, which is made in accordance with the
requirements of the EU Market Abuse Regulation, provides further
details.
1 Details of the person discharging managerial responsibilities/person
closely associated
a) Name Peter Pack
-------------------------- ---------------------------------------------
2 Reason for the notification
-------------------------------------------------------------------------
a) Position/status Director/PDMR
-------------------------- ---------------------------------------------
b) Initial notification/ Initial notification
Amendment
-------------------------- ---------------------------------------------
3 Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
-------------------------------------------------------------------------
a) Name Oxford BioDynamics Plc
-------------------------- ---------------------------------------------
b) LEI 2138005Y1TK258O5U928
-------------------------- ---------------------------------------------
4 Details of the transaction(s): section to be repeated for (i)
each type of instrument; (ii) each type of transaction; (iii)
each date; and (iv) each place where transactions have been
conducted
-------------------------------------------------------------------------
a) Description of the Ordinary Shares of 1 pence each
financial instrument, ISIN: GB00BD5H8572
type of instrument
Identification code
-------------------------- ---------------------------------------------
b) Nature of the transaction Grant of share options
-------------------------- ---------------------------------------------
c) Price(s) and volume(s) 210,000 ordinary shares at an exercise price
of 100 pence per share
-------------------------- ---------------------------------------------
d) Aggregated information N/A
- Aggregated volume
- Price
-------------------------- ---------------------------------------------
e) Date of the transaction 8 July 2020
-------------------------- ---------------------------------------------
f) Place of the transaction Outside a trading venue
-------------------------- ---------------------------------------------
For further details please contact:
Oxford BioDynamics Plc
Jon Burrows, CEO
Paul Stockdale, CFO +44 (0)1865 518910
Shore Capital
Nominated Adviser and Broker
Stephane Auton
Edward Mansfield +44 (0)20 7408 4090
FTI Consulting
Financial Public Relations
Adviser
Natalie Garland-Collins +44 (0)20 3727 1000
Notes for Editors
About Oxford BioDynamics Plc
Oxford BioDynamics Plc (AIM: OBD) ("Oxford BioDynamics") is a
biotechnology company focused on the discovery and development of
epigenetic biomarkers for use within the pharmaceutical and
biotechnology industry.
The Company's award-winning, proprietary technology platform,
EpiSwitch(TM), aims to accelerate the drug discovery and
development process, improve the success rate of therapeutic
product development and take advantage of the increasing importance
of personalised medicine.
In particular, EpiSwitch(TM) can reduce time to market, failure
rates and the costs at every stage of drug discovery. Additionally,
the technology provides significant insights into disease
mechanisms for drug discovery and product re--positioning
programmes and enables the personalisation of therapeutics for
patients in the context of challenging pricing environments where
improved clinical outcomes are critical.
In April 2019, Oxford BioDynamics received the Queen's Award for
Enterprise: Innovation. The Queen's Awards for Enterprise are the
most prestigious awards for UK businesses.
Oxford BioDynamics is headquartered in the UK, and listed on the
London Stock Exchange's AIM under the ticker "OBD". For more
information please visit www.oxfordbiodynamics.com .
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
DSHKDLFBBDLBBBE
(END) Dow Jones Newswires
July 08, 2020 02:00 ET (06:00 GMT)
Oxford Biodynamics (LSE:OBD)
Historical Stock Chart
From Apr 2024 to May 2024
Oxford Biodynamics (LSE:OBD)
Historical Stock Chart
From May 2023 to May 2024